A 2-year, 6-month-old girl presented with a large abdominal mass. A computed tomography scan revealed a tumor B12 cm in diameter arising from the left adrenal gland. A complete blood count showed a WBC count of 9.39 Â 10 9 /L, hemoglobin 9.1 g/dL, and platelets 431 Â 10 9 /L. She had an elevated urinary vanillylmandelic acid level of 9.94 mg/day, and a serum lactate dehydrogenase level of 1968 IU/L. A BM biopsy was performed, and the pathological examination revealed invasion of neuroblastoma cells that were positive for neuron-specific enolase and synaptophysin. A technetium-99 bone scan demonstrated multiple bony metastases.
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A diagnosis of stage 4 neuroblastoma was made, and she began preoperative chemotherapy, as suggested by the N2002-HR2 regimen of the Taiwan Pediatric Oncology Group. The induction chemotherapy included three cycles of CDV (CY, vincristine and adriamycin) and two cycles of CiE (etoposide and cisplatin). Subsequently, the residual tumor, which was about 4 cm in diameter, was nearly totally resected. According to the protocol, she received an additional cycle of CDV after the operation.
When she was born, her cord blood (CB) was collected and stored at a private CB bank. After discussing with her parents and obtaining written, informed consent, a decision was made to carry out an autologous CB transplantation (CBT). Without TBI, the conditioning regimen consisted of carboplatin, etoposide and melphalan. A total of 67.8 Â 10 6 /kg nucleated cells, derived from the CB, were infused. It took 12 and 15 days to achieve neutrophil and platelet engraftment, respectively. No severe transplantrelated complications were noted. The adjuvant therapy after transplantation included irradiation to the primary tumor site (21.6 Gy) and 13-cis retinoic acid for 6 months. Without evidence of recurrence on the follow-up CT scans and I 123 -meta-iodobenzylguanidine scintigraphies, the patient was doing well in CR with normalized urine vanillylmandelic acid levels at the time of preparing this manuscript (24 months after transplantation).
Neuroblastoma is the most common extracranial tumor in pediatric patients. However, the outcome of stage 4 neuroblastoma in children over 1 year of age remains poor despite improving survival rates of childhood cancers. Compared with traditional maintenance chemotherapy, intensification of consolidation therapy with autologous hematopoietic stem cell (HSC) rescue after myeloablative chemotherapy has contributed to the improved outcomes. [1] [2] [3] In the N2002 trial in Taiwan, 45 of 107 non-infant patients with stage 4 neuroblastoma received highdose chemotherapy followed by autologous PBSC transplantation. And they had a better 5-year overall survival (47% vs 26%, P ¼ 0.01) and PFS rates (28% vs 11%, P ¼ 0.009) than those who received traditional maintenance chemotherapy. In our hospital, we have performed autologous PBSC transplantation on 12 patients with stage 4 neuroblastoma ( Table 1 ). All of the patients achieved hematopoietic engraftment, and the time to neutrophil and platelet engraftment ranged from 9 to 17 days and 10 to 21 days, respectively. However, 6 of the 12 patients experienced a relapse or died, and the median time to progression was 12 months after transplantation (range, 4-22 months). In comparison, although there was a relatively small quantity of CD34 þ cells from the CB, the time to achieve hematopoietic engraftment was not longer for the patient in this study.
High-risk neuroblastoma is the most common indication for autologous HSC transplantation in children, 4 and PBSCs are now the most common source of HSCs.
1-3 Although a concern for PBSC collection and reinfusion in these patients is the potential risk of reinfusion of neuroblastoma tumor cells that may contribute to relapse, 5, 6 Kreissman et al. 7 reported that centralized immunomagnetic purging of PBSCs did not impact the effect-free and overall survival rates at 2 years. The risk of contamination may be lower if CB is the source of HSCs. 4 However, available data focusing on autologous CBT for neuroblastoma is very limited. Further work needs to be carried out to compare the outcomes of patients with neuroblastoma undergoing autologous PBSC transplantation and CBT. In addition, to minimize the tumor burden as much as possible, intensive induction regimens are currently used before PBSC collection. Consequently, the time needed to harvest sufficient autologous PBSCs becomes longer, and it took more than 5 contiguous days to obtain sufficient cells in half of our patients. Additionally, some of the suffering before and during PBSC collection can be omitted if autologous CB is available. The procedures and the time needed for leukapheresis are uncomfortable, especially for young children. Subcutaneous administration of G-CSF is painful, and the risks of using central lines or arterial lines, such as hemorrhage and occlusion, may be higher in children.
CB has been identified as a good source of HSCs; however, the experience of autologous CBT in children with malignancies is very limited. 8, 9 With the increasing frequency of private CB collection and storage, there will certainly be more opportunities for autologous CBT in the future. Hence, our experience of the successful use of autologous CB as the only HSC source in a child with stage 4 neuroblastoma may be useful.
